Bovine antibody-based oral immunotherapy for reduction of intragastric Helicobacter pylori colonization: A randomized clinical trial

Canadian Journal of Gastroenterology

Volumn 25, Issue 4, 2011, Pages 207-213

  Den Hoed, C M ^a   De Vries, A C ^a   Mensink, P B F ^a   Dierikx, C M ^a   Suzuki, H ^b   Capelle, L ^a   Van Dekken, H ^a   Ouwendijk, R ^c   Kuipers, E J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c IKAZIA HOSPITAL   (Netherlands)

Author keywords

Eradication treatment; Gastritis; H pylori; Immunotherapy

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIUM ANTIBODY; BOVINE ANTI HELICOBACTER PYLORI ANTIBODY; UNCLASSIFIED DRUG; WHEY PROTEIN CONCENTRATE; WPC 80;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL LOAD; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTRITIS; GASTROSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MALE; ORAL IMMUNOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UREA BREATH TEST;

EID: 80054736163     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2011/672093     Document Type: Article

References (46)

1. Goodwin CS, Mendall MM, Northfield TC. Helicobacter pylori infection. Lancet 1997;349:265-9. (Pubitemid 27051003)
2. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995;345:1525-8.
3. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19:449-90. (Pubitemid 44134306)
4. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht III Consensus Report. Gut 2007;56:772-81. (Pubitemid 46854190)
5. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: The efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-82. (Pubitemid 39657940)
6. Gerrits MM, van Vliet AH, Kuipers EJ, et al. Helicobacter pylori and antimicrobial resistance: Molecular mechanisms and clinical implications. Lancet Infect Dis 2006;6:699-709. (Pubitemid 44601991)
7. Davidson GP, Whyte PB, Daniels E, et al. Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus. Lancet 1989;2:709-12. (Pubitemid 19243115)
8. Mitra AK, Mahalanabis D, Ashraf H, et al. Hyperimmune cow colostrum reduces diarrhoea due to rotavirus: A double-blind, controlled clinical trial. Acta Paediatr 1995;84:996-1001.
9. Tollemar J, Gross N, Dolgiras N, et al. Fungal prophylaxis by reduction of fungal colonization by oral administration of bovine anti-Candida antibodies in bone marrow transplant recipients. Bone Marrow Transplant 1999;23:283-90. (Pubitemid 29078343)
10. Torres O, Cruz JR. Protection against Campylobacter diarrhea: Role of milk IgA antibodies against bacterial surface antigens. Acta Paediatr 1993;82:835-8. (Pubitemid 23291855)
11. van Dissel JT, de Groot N, Hensgens CM, et al. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: Preclinical and preliminary clinical data. J Med Microbiol 2005;54:197-205. (Pubitemid 40868008)
12. Casswall TH, Nilsson HO, Bjorck L, et al. Bovine anti-Helicobacter pylori antibodies for oral immunotherapy. Scand J Gastroenterol 2002;37:1380-5. (Pubitemid 36051498)
13. Marnila P, Rokka S, Rehnberg-Laiho L, et al. Prevention and suppression of Helicobacter felis infection in mice using colostral preparation with specific antibodies. Helicobacter 2003;8:192-201. (Pubitemid 36712403)
14. Thomas JE, Austin S, Dale A, et al. Protection by human milk IgA against Helicobacter pylori infection in infancy. Lancet 1993;342:121. (Pubitemid 23192448)
15. Weiner C, Pan Q, Hurtig M, et al. Passive immunity against human pathogens using bovine antibodies. Clin Exp Immunol 1999;116:193-205. (Pubitemid 29219713)
16. Casswall TH, Sarker SA, Albert MJ, et al. Treatment of Helicobacter pylori infection in infants in rural Bangladesh with oral immunoglobulins from hyperimmune bovine colostrum. Aliment Pharmacol Ther 1998;12:563-8. (Pubitemid 28289446)
17. Oona M. Helicobacter pylori in children with abdominal complaints: Has immuni bovine colostrum some influence on gastritis? Alpe Adria Microbiol J 1997;6:49-57. (Pubitemid 27337245)
18. Opekun AR, El-Zaimaity HM, Osato MS, et al. Novel therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 1999;13:35-42.
19. Ando KN, T. A method for producing a new medicine for both treating and preventing peptic ulcer diseases and gastritis and thus formulated medicines. European Patent Office 1991:1-14.
20. Tarpila SK, H. Immune colostrum in the treatment of Helicobacter pylori gastritis. 24th Int Diary Congress. Melbourne, Australia: Brief Communications 1994:293.
21. Dimenas E, Glise H, Hallerback B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993;28:681-7. (Pubitemid 23231987)
22. Dimenas E, Glise H, Hallerback B, et al. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995;30:1046-52.
23. Cats A, Kuipers EJ, Bosschaert MA, et al. Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther 2003;17:429-35. (Pubitemid 36259406)
24. Clyne M, Thomas J, Weaver L, et al. In vitro evaluation of the role of antibodies against Helicobacter pylori in inhibiting adherence of the organism to gastric cells. Gut 1997;40:731-8. (Pubitemid 27305465)
25. Early EM, Hardy H, Forde T, et al. Bactericidal effect of a whey protein concentrate with anti-Helicobacter pylori activity. J Appl Microbiol 2001;90:741-8. (Pubitemid 32391780)
26. Shin JH, Yang M, Nam SW, et al. Use of egg yolk-derived immunoglobulin as an alternative to antibiotic treatment for control of Helicobacter pylori infection. Clin Diagn Lab Immunol 2002;9:1061-6. (Pubitemid 34988476)
27. Suzuki H, Nomura S, Masaoka T, et al. Effect of dietary anti-Helicobacter pylori-urease immunoglobulin Y on Helicobacter pylori infection. Aliment Pharmacol Ther 2004;20 Suppl 1:185-92. (Pubitemid 39120292)
28. Dial EJ, Hall LR, Serna H, et al. Antibiotic properties of bovine lactoferrin on Helicobacter pylori. Dig Dis Sci 1998;43:2750-6. (Pubitemid 29034932)
29. Okuda M, Nakazawa T, Yamauchi K, et al. Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: A randomized, double-blind, placebo-controlled study. J Infect Chemother 2005;11:265-9. (Pubitemid 41821511)
30. Huynh HQ, Campbell MA, Couper RT, et al. Lactoferrin and desferrioxamine are ineffective in the treatment of Helicobacter pylori infection and may enhance H pylori growth and gastric inflammation in mice. Lett Appl Microbiol 2009.
31. Zou J, Dong J, Yu XF. Meta-analysis: The effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy. Helicobacter 2009;14:119-27.
32. Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001;15:163-9. (Pubitemid 32142492)
33. Canducci F, Armuzzi A, Cremonini F, et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000;14:1625-9. (Pubitemid 32011735)
34. de Bortoli N, Leonardi G, Ciancia E, et al. Helicobacter pylori eradication: A randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol 2007;102:951-6. (Pubitemid 46698221)
35. Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: A systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2009;21:45-53.
36. Herrmann JE. DNA vaccines against enteric infections. Vaccine 2006;24:3705-8.
37. Sun B, Li ZS, Tu ZX, et al. Construction of an oral recombinant DNA vaccine from H pylori neutrophil activating protein and its immunogenicity. World J Gastroenterol 2006;12:7042-6. (Pubitemid 44834899)
38. Agarwal K, Agarwal S. Helicobacter pylori vaccine: From past to future. Mayo Clin Proc 2008;83:169-75. (Pubitemid 351303101)
39. Malfertheiner P, Schultze V, Rosenkranz B, et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: A phase I study. Gastroenterol 2008;135:787-95.
40. Velin D, Michetti P. Advances in vaccination against Helicobacter pylori. Expert Rev Gastroenterol Hepatol 2010;4:157-66.
41. Rokkas T, Sechopoulos P, Robotis I, et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009;104:21-5.
42. Hojo M, Miwa H, Nagahara A, et al. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001;36:690-700. (Pubitemid 32573708)
43. Seppälä K, Kosunen TU, Nuutinen H, et al. Cure of Helicobacter pylori infection after failed primary treatment: One-center results from 120 patients. Scand J Gastroenterol 2000;35:929-34.
44. Pontone S, Standoli M, Angelini R, et al. Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice. Dig Liver Dis 2010;42:541-3.
45. Kearney DJ, Brousal A. Treatment of Helicobacter pylori infection in clinical practice in the United States: Results from 224 patients. Dig Dis Sci 2000;45:265-71. (Pubitemid 30133884)
46. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: A randomized trial. Ann Intern Med 2007;146:556-63. (Pubitemid 351650536)